- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Commercial Services
- Sub-Industry: Research&Development
AVEO Pharmaceuticals Inc
+ Add to WatchlistAVEO:US
2.7100 USD 0.0100 0.37%As of 20:10:00 ET on 05/24/2013.
Snapshot for AVEO Pharmaceuticals Inc (AVEO)
| Open: | 2.3500 | Day's Range: | 2.2900 - 2.7100 | Volume: | 3,462,710 |
|---|---|---|---|---|---|
| Previous Close: | 2.7100 | 52wk Range: | 2.2500 - 14.0800 | 1-Yr Rtn: | -78.49% |
Key Statistics for AVEO
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -2.4900 |
| Est. EPS (USD) (12/2013) | -2.3920 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 140.61 |
| Shares Outstanding (M) | 51.89 |
| 30 Day Average Volume | 3,659,996 |
| Price/Book (mrq) | 0.9952 |
| Price/Sale (ttm) | 6.2956 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for AVEO
Company Profile & Key Executives for AVEO
Aveo Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics. The Company's lead product candidate is an oral inhibitor of the vascular endothelial growth factor, or VEGF,receptors.
| Tuan Ha-NgocPresident/CEO | David B JohnstonChief Financial Officer |
| William SlichenmyerChief Medical Officer | Michael P BaileyChief Commercial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
AVEO News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page